Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of PDD during TURB for NMIBC
2024-514316-27-00Phase 4Authorised
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of hexaminolevulinate in bladder cancer (2 arms), sponsored by AOU Città della Salute e della Scienza di Torino. Primary endpoint: Residual tumour and/or new diagnosis of carcinoma in situ (CIS) at re-TUR. Planned start Oct 2025; status: authorised.
02
Drugs
hexaminolevulinate
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2024-514316-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514316-27-00.